Editorial Board — Medscape HIV/AIDS

Board Members

  • John G. Bartlett, MD
    • Johns Hopkins University School of Medicine
      The Johns Hopkins Hospital
      Baltimore, Maryland
  • Veronica Miller, PhD
    • George Washington School of Public Health
      Forum for Collaborative HIV Research
      School of Public Health, UC Washington Center
      Washington, DC
  • Kogieleum K. Naidoo, MBChB
    • Senior Scientist, Head of TB HIV Treatment Research Programme
      Centre for the AIDS Programme of Research in South Africa (CAPRISA)
      Nelson R. Mandela School of Medicine
      University of KwaZulu-Natal, Durban
      KwaZulu-Natal, South Africa
  • Paul E. Sax, MD
    • Harvard Medical School
      Brigham and Women's Hospital
      Boston, Massachusetts
 

Board Member Details

John G. Bartlett, MD
John G. Bartlett, MD

Professor Emeritus, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland

John G. Bartlett, MD, has disclosed no relevant financial relationships.

Veronica Miller, PhD
Veronica Miller, PhD

Research Professor, George Washington School of Public Health; Executive Director, Forum for Collaborative HIV Research; Visiting Professor, School of Public Health, UC Washington Center, Washington, DC

Veronica Miller, PhD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: ViiV
Veronica Miller is an employee of the Forum for Collaborative HIV Research. Over the last two years, the Forum has received unrestricted educational or research grants from:
Abbott Laboratories; AbbVie; Achillion Pharmaceuticals, Inc.; Alere; Astellas Pharma, Inc; Astra-Zeneca Pharmaceuticals LP; Biogen Idec Inc; BioRAD; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Cell Medica; Chimerix, Inc; Cocrystal Pharma, Inc; Covance; DDL Diagnostics; DeuteRx; DiaPharma; DS Biopharma; Echosens; Exalenz; FibroGen, Inc.; Fractyl; Galectin Therapeutics; Genentech, Inc.; GENFIT SA; Gilead Sciences, Inc.; GlaxoSmithKline; Icon; Illumina, Inc.; Immuron; Intercept; Ortho-McNeil-Janssen Pharmaceuticals, Inc.; Kaiser Permanente; LabCorp; Eli Lilly and Company; Madrigal Pharmaceuticals; Mallinckrodt Pharmaceuticals; MediciNova; Medivir; Merck & Co., Inc.; Microbiotix; Monogram Biosciences, Inc.; Mylan; NGM Biopharmaceuticals; Nimbus Therapeutics; Nitto Denko Technical Corp; Novartis Pharmaceuticals Corporation; Novo Nordisk Inc; Nusirt; Orasure; OWL Metabolomics; Pacific Biosciences, Inc.; Pfizer Inc; PPD, Inc.: Presidio; Qiagen; Quest Diagnostics; Quintiles Transnational Corp.; Raptor Pharmaceuticals; Resonance Health; Roche Molecular Diagnostics; Rooivant Sciences; RuiTi; SeraCare; Schinazi Family Foundation; Shire; Takeda Pharmaceuticals North America, Inc.; Tobira Therapeutics; ViiV Healthcare; VLVBio; and Zafgen

Kogieleum K. Naidoo, MBChB
Kogieleum K. Naidoo, MBChB

Kogieleum K. Naidoo, MBChB, Senior Scientist, Head of TB HIV Treatment Research Programme, Centre for the AIDS Programme of Research in South Africa (CAPRISA), Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, KwaZulu-Natal, South Africa

Kogieleum K. Naidoo, MBChB, has disclosed the following relevant financial relationships:
Serve(d) as a speaker or a member of a speakers bureau for: Gilead Sciences, Inc.
Received research grant from: US Centers for Disease Control and Prevention; US Agency for International Development; National Institutes of Health
Received income in an amount equal to or greater than $250 from: Centre for the AIDS Programme of Research in South Africa; Gilead Sciences, Inc.

Paul E. Sax, MD
Paul E. Sax, MD

Professor of Medicine, Harvard Medical School; Clinical Director, Department of Medicine, Division of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts

Paul E. Sax, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: AbbVie; Bristol-Myers Squibb; Gilead; GlaxoSmithKline/ViiV; Merck; Ortho-McNeil-Janssen Pharmaceuticals, Inc
Received a research grant from: Bristol-Myers Squibb; Gilead; GlaxoSmithKline/ViiV